IceCure Medical presented data at ECIO 2026 showing its ProSense® cryoablation system achieved an 89.4% recurrence-free rate for kidney tumors ≤3 cm at 5 years. The technology also showed promising results in early-stage breast cancer and fibroadenoma treatments, with high patient satisfaction and minimal complications. ProSense® is FDA-cleared for low-risk breast cancer and offers a minimally invasive alternative to surgery, expanding its global adoption and clinical interest. This growing momentum suggests ProSense® could become a standard treatment option in oncology.
Bluebeam has launched Bluebeam Max, a premium AI-powered subscription for architecture, engineering, and construction (AEC) professionals worldwide. The tool offers advanced automation, intelligent markups, and AI-driven review features that reduce m...
Armada has opened a new headquarters in Marshall Township, Pittsburgh, expanding its space from 20,000 to 90,000 square feet to support over 300 employees. This move triples its footprint and enhances collaboration, employee experience, and scalabili...
Ventripoint Diagnostics, a Toronto-based AI medtech company, is gaining regulatory and commercial validation for its VMS+ 4.0 cardiac imaging system, recently submitted for approval in China via an expedited pathway. The technology provides MRI-equiv...
Potomac Bank has appointed Scott H. Moore as Senior Vice President and Market President to lead its expansion into the Winchester and Frederick County region in Virginia. Moore, a Winchester native with extensive banking experience, will oversee the ...
Worldwide NFT, Inc. announced that Jay Wright has acquired majority voting control from George Sharp, effective immediately. Wright, with extensive experience in M&A and leadership roles in tech and defense companies, plans to pursue growth through a...
